Tech Center 1600 • Art Units: 1624
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18629562 | HETEROCYCLIC FLAVONE DERIVATIVES, COMPOSITIONS, AND METHODS RELATED THERETO | Non-Final OA | EMORY UNIVERSITY |
| 18251111 | CRYSTALLINE FORM IV OF MELANOCORTIN RECEPTOR AGONIST COMPOUND AND PREPARATION METHOD THEREFOR | Non-Final OA | LG CHEM, LTD. |
| 18018207 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18255767 | COMPOUNDS AND THEIR USE FOR TREATING NEUROPATHIC PAIN | Non-Final OA | The Johns Hopkins University |
| 17617546 | COMPOSITIONS AND METHODS FOR TREATING CANCER | Non-Final OA | The Regents of the University of Michigan |
| 17430077 | MONONUCLEAR IRIDIUM COMPLEXES CONTAINING THREE ORTHO-METALLATED BIDENTATE LIGANDS AND OPTICAL ORIENTATING ANISTROPHY | Non-Final OA | UDC IRELAND LIMITED |
| 18268102 | METHODS OF TREATING NEURODEGENERATIVE DISORDERS AND STAT3-LINKED CANCERS USING SUPPRESSORS OF ELECTRON LEAK | Non-Final OA | Cornell University |
| 17596491 | TARGETING DNA REPAIR IN TUMOR CELLS VIA INHIBITION OF ERCC1-XPF | Non-Final OA | The Governors of the University of Alberta |
| 17906742 | AMINOPYRIMIDINE DERIVATIVES AND THEIR USE AS ARYL HYDROCARBON RECEPTOR MODULATORS | Final Rejection | DONG-A ST CO., LTD. |
| 17919402 | SOLID PHARMACEUTICAL PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF | Non-Final OA | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. |
| 17909260 | IMIDAZOLE-BASED SYNTHETIC LIPIDOIDS FOR IN VIVO MRNA DELIVERY INTO IMMUNE CELLS | Final Rejection | Trustees of Tufts College |
| 17790835 | AURISTATIN-RELATED COMPOUNDS, CONJUGATED AURISTATIN-RELATED COMPOUNDS, AND METHODS OF USE THEREOF | Final Rejection | CYTOMX THERAPEUTICS, INC. |
| 18289476 | NOVEL TRYPTAMINES AND METHODS OF TREATING MOOD DISORDERS | Non-Final OA | GILGAMESH PHARMACEUTICALS INC. |
| 17996028 | CRYSTALLINE RET INHIBITOR | Final Rejection | Loxo Oncology, Inc. |
| 18246566 | SIPONIMOD SALTS AND COCRYSTALS | Non-Final OA | Synthon B.V. |
| 18272162 | PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-SULFONAMIDE DERIVATIVES FOR THE INHIBITION OF SGK-1 | Non-Final OA | THRYV THERAPEUTICS INC. |
| 18270288 | Anti-Tumor Compositions and Methods | Non-Final OA | Evrys Bio, LLC |
| 18269783 | PHARMACEUTICAL COMPOSITION CONTAINING PYRROLOQUINOLINE QUINONE TRILITHIUM SALT NONAHYDRATE COMPOUND, CAPSULE, AND PREPARATION METHOD THEREFOR | Non-Final OA | SHANGHAI RAISING PHARMACEUTICAL CO., LTD |
| 18028286 | METTL3 INHIBITORY COMPOUNDS | Non-Final OA | Storm Therapeutics Limited |
| 17605676 | NUCLEOSIDE DERIVATIVE FOR PREVENTING AND TREATING INFLAMMATION AND APPLICATION THEREOF | Final Rejection | WEST CHINA HOSPITAL OF SICHUAN UNIVERSITY |
| 18155281 | METHODS OF EXTENDING LIFESPAN BY ADMINISTERING FERROPTOSIS INHIBITORS | Non-Final OA | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC |
| 17438158 | Heteroaromatic and Heterobicyclic Aromatic Derivatives for the Treatment of Ferroptosis-Related Disorders | Non-Final OA | COLLABORATIVE MEDICINAL DEVELOPMENT, LLC |
| 17792027 | Cell Surface Receptor Binding Compounds and Conjugates | Final Rejection | Lycia Therapeutics, Inc. |
| 18060323 | COMPOSITIONS COMPRISING LACTATE DEHYDROGENASE-A INHIBITORS AND METHODS OF PRODUCTION AND USE THEREOF | Non-Final OA | Southwestern Oklahoma State University |
| 17802558 | Pharmaceutical compositions comprising 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate and sodium ions | Final Rejection | AIC246 AG & Co. KG |
| 17309450 | METHODS OF MODULATING LEUKOCYTES ACTIVATION AND THROMBOCYTE CLEARANCE WITH INHIBITORS OF SPECIFIC NEURAMINIDASE ISOENZYMES | Final Rejection | Valorisation HSJ, Limited Partnership |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy